3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1
4
Phase 3
3
Phase 1/2
2
Status
Completed
2
Unknown
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Conditions
Breast Neoplasms
70
Lymphoma
54
Lymphoma, Large B-Cell, Diffuse
40
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Hodgkin Disease
26
Sarcoma
25
Lymphoma, Follicular
25
Lymphoma, Non-Hodgkin
24
Leukemia
19
Burkitt Lymphoma
17
Multiple Myeloma
16
Endometrial Neoplasms
15
Neuroblastoma
14
Ovarian Neoplasms
12
Carcinoma, Hepatocellular
12
Lymphoma, Large-Cell, Immunoblastic
11
Lymphoma, Mantle-Cell
10
Liposarcoma
9
Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
8
Leiomyosarcoma
8
Histiocytoma, Malignant Fibrous
8
Urinary Bladder Neoplasms
7
Lymphoma, B-Cell, Marginal Zone
7
Hemangiosarcoma
7
Fibrosarcoma
7
Wilms Tumor
6
Triple Negative Breast Neoplasms
6
Sarcoma, Synovial
6
Neurofibrosarcoma
6
Interventions
Doxorubicin
3
10-propargyl-10-deazaaminopterin
3
Vincristine
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Gemcitabine
2
Drug Therapy
2
Cyclophosphamide
2
Alemtuzumab
2
romidepsin
1
cc-486
1
belinostat
1
Vitamin B 12
1
Stem Cell Transplantation
1
Standard of Care
1
Specimen Handling
1
Prednisone
1
Practice Guidelines as Topic
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Leukapheresis
1
Hematopoietic Stem Cell Mobilization
1
Folic Acid
1
Etoposide
1
Cytarabine
1
Cladribine
1
Carmustine
1
Busulfan
1
Brentuximab Vedotin
1
Biopsy
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, T-Cell
×
Doxorubicin
×
Clear all
NCT01777152
2021-11-30
ECHELON-2
Seagen Inc.
Phase 3
Completed
452 enrolled
16 charts
1 FDA
NCT00646854
2019-03-01
ACT-1
University of Aarhus
Phase 3
Completed
136 enrolled
NCT00725231
2012-05-07
A-CHOP-14
University of Göttingen
Phase 3
Unknown
274 enrolled